Uncategorized
Sight Sciences receives IDE approval to initiate clinical trial of ab interno canaloplasty system vs. SLT
Sight Sciences received full investigational device exemption approval from the FDA to initiate a clinical trial comparing ab interno canaloplasty and selective laser trabeculoplasty, according to a press release. The multicenter, prospective, randomized, controlled clinical trial will evaluate the safety and efficacy of the Visco360 viscosurgical system in reducing IOP in patients with primary open-angle glaucoma vs. SLT.